Immune checkpoint inhibitors–related encephalitis in melanoma and non-melanoma cancer patients: a single center experience
Authors:
Open Access
- 12 June 2021
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 29 (12) , 7563-7568
Abstract
Background: Treatment with immune checkpoint inhibitors (ICI) has greatly improved survival for patients with a number of malignant diseases in recent years. Neurological immune-related adverse events (n-irAE) of varying severity have been reported in the literature. We aimed to identify the incidence of n-irAE, focusing on immune-related encephalitis (IRE), in patients treated with ICI for multiple non-hematological malignancies in our institution. Methods: All patients with histologically verified cancer that received treatment with ICI at the Sheba Medical Center between January 2017 and August 2019 were surveyed. Medical records for each patient were reviewed and information regarding n-irAE was recorded. Results: In total, 1993 patients were included. Eleven cases of IRE were recorded, affecting 0.55% of patients overall, eight had non-melanoma cancer. Eight patients had made a full recovery. Conclusions: IRE is a n-irAE more frequent than previously reported, particularly in non-melanoma patients. The diagnostic criteria and optimal treatment needs to be determined. ICI re-challenge after IRE can be considered for selected patients.Keywords
This publication has 28 references indexed in Scilit:
- Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectivesNature Reviews Neurology, 2017
- Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) AntibodiesJAMA Neurology, 2017
- Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic reviewAnnals of Oncology, 2017
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of EncephalitisThe Oncologist, 2017
- Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancerExpert Opinion on Drug Safety, 2017
- Neurological adverse events associated with immune checkpoint inhibitors: Review of the literatureEuropean Journal of Cancer, 2017
- Novel immune check point inhibiting antibodies in cancer therapy—Opportunities and challengesDrug Resistance Updates, 2017
- Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literatureAnnals of Oncology, 2016
- Paraneoplastic neurological syndromesClinical and Experimental Immunology, 2014